RBC
HAE icon

Romano Brothers & Co’s Haemonetics HAE Stock Holding History

Romano Brothers & Co’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-400
Closed -$31.5K – 565
2022
Q4 		$31.5K Buy
+400
New +$32.1K ﹤0.01% 539

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Romano Brothers & Co's HAE Position: Q1 2023 in Review

Romano Brothers & Co sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 400 shares — an estimated $31.5K sold.

Romano Brothers & Co first reported a position in HAE in Q4 2022 and held it in 1 quarter. The position peaked at $31.5K in Q4 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

  • Romano Brothers & Co reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
  • Romano Brothers & Co sold 400 Haemonetics shares in Q1 2023, an estimated $31.5K.
  • Romano Brothers & Co first reported a position in Haemonetics in Q4 2022 and held it in 1 quarter.
  • Romano Brothers & Co's Haemonetics position peaked at $31.5K in Q4 2022.
  • 301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.